Acetylcholine Receptor Antibody Positivity, RNST Abnormality, and Thymoma Predict Generalization in Ocular Myasthenia Gravis: A South Korean Cohort Study.
Overview
- School of Medicine, Konkuk University, Chungju-si 27478, Republic of Korea; (H.J.S.); (C.K.)
- Department of Ophthalmology, Konkuk University Medical Center, Seoul 05030, Republic of Korea
- Research Institute of Medical Science, Konkuk University, Seoul 05029, Republic of Korea
- Department of Neurology, Konkuk University Medical Center, Seoul 05030, Republic of Korea
Abstract
Background: Ocular myasthenia gravis (OMG) can remain restricted to ocular symptoms or progress to generalized myasthenia gravis (GMG). However, the rate of generalization and its predictors may vary across populations, and data on South Korean patients remain inadequate. This study investigated the conversion rate from OMG to GMG and identified clinical, serologic, electrophysiologic, and thymic predictors of this generalization in a South Korean cohort. Methods: This retrospective cohort study included 89 patients who initially presented with OMG and were followed up for at least 2 years. The primary outcome was conversion to GMG during follow-up. The investigated predictors included demographic variables, initial ocular manifestations, acetylcholine receptor antibody (AChR-Ab) status and titer, repetitive nerve stimulation test (RNST) findings, thymic abnormalities, and immunosuppressive treatment. Kaplan–Meier analyses and Cox proportional-hazards models were used to evaluate the GMG-free survival rate and risk factors for conversion. Results: During follow-up, 10 patients (11.2%) progressed to GMG, with this conversion occurring within 2 years in 8 patients (9.0%). All converters were AChR-Ab positive. AChR-Ab positivity, RNST positivity, thymic abnormality, and thymoma were associated with GMG conversion in univariable analyses. RNST positivity in any tested muscle (hazard ratio [HR] = 12.66, 95% confidence interval [CI] = 2.68–59.76, p = 0.001) and thymoma (HR = 10.67, 95% CI = 3.06–37.27, p < 0.001) was associated with generalization. These associations persisted in the restricted multivariable Cox model. Conclusions: The rate of GMG conversion was relatively low in this South Korean OMG cohort, and most conversions occurred within 2 years. The presence of AChR-Ab positivity, RNST abnormality, or thymoma may characterize high-risk patients who require closer monitoring during the early disease course.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- figshare:32573280 — at figshare; found in “Data Availability Statement”
Data Availability Statement
The minimal anonymized dataset required to reproduce the findings of our study has been deposited in a public repository (Figshare) and is accessible via the following DOI: http://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 27 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 3 authors, 5 keywords, 2 funders, 33 references.
Cite
This paper
Shin, H. J., Kwon, C., & Oh, J. (2026). Acetylcholine Receptor Antibody Positivity, RNST Abnormality, and Thymoma Predict Generalization in Ocular Myasthenia Gravis: A South Korean Cohort Study. Antibodies (Basel, Switzerland), 15(4), 73. https://
BibTeX
@article{shin2026acetylc
author = {Shin, Hyun Jin and Kwon, Chaerin and Oh, Jeeyoung},
title = {{Acetylcholine Receptor Antibody Positivity, RNST Abnormality, and Thymoma Predict Generalization in Ocular Myasthenia Gravis: A South Korean Cohort Study}},
journal = {Antibodies (Basel, Switzerland)},
year = {2026},
month = aug,
volume = {15},
number = {4},
pages = {73},
publisher = {Multidisciplinary Digital Publishing Institute (MDPI)},
issn = {2073-4468},
doi = {10.3390/
url = {https://
pmid = {42645431},
pmcid = {PMC13509972}
}
RIS
TY - JOUR
AU - Shin, Hyun Jin
AU - Kwon, Chaerin
AU - Oh, Jeeyoung
TI - Acetylcholine Receptor Antibody Positivity, RNST Abnormality, and Thymoma Predict Generalization in Ocular Myasthenia Gravis: A South Korean Cohort Study
T2 - Antibodies (Basel, Switzerland)
J2 - Antibodies (Basel)
PY - 2026
DA - 2026/
VL - 15
IS - 4
SP - 73
SN - 2073-4468
PB - Multidisciplinary Digital Publishing Institute (MDPI)
DO - 10.3390/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.3390/
"type": "article-journal",
"title": "Acetylcholine Receptor Antibody Positivity, RNST Abnormality, and Thymoma Predict Generalization in Ocular Myasthenia Gravis: A South Korean Cohort Study",
"container-title": "Antibodies (Basel, Switzerland)",
"author": [
{
"family": "Shin",
"given": "Hyun Jin"
},
{
"family": "Kwon",
"given": "Chaerin"
},
{
"family": "Oh",
"given": "Jeeyoung"
}
],
"container-title-short":
"volume": "15",
"issue": "4",
"page": "73",
"DOI": "10.3390/
"PMID": "42645431",
"PMCID": "PMC13509972",
"ISSN": "2073-4468",
"publisher": "Multidisciplinary Digital Publishing Institute (MDPI)",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
8,
11
]
]
}
}
Similar papers
No other paper with a page shares enough with this one yet: tools, categories, datasets, references or authors.
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.